Pozen kept at outperform by RBC

RBC Capital Markets analyst Ken Trbovich reiterated Pozen Inc. at outperform, speculative risk, and a $15 price target on the likelihood of Trexima gaining approval based upon evidence that naproxen does not carry added cardiovascular risk. Concerns about the cardiovascular risk of Vioxx cast a pall across the entire class of non-steroidal anti-inflammatory drugs (Nsaids), according to the analyst. The head of the American College of Cardiology sees naproxen as the safest choice for pain relief among the Nsaid drug class. Shares of the Chapel Hill, N.C.-based development-stage company were up 41 cents, or 3.44%, at $12.33. (Nasdaq: POZN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.